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ABSTRACT The fungal kingdom includes at least 6 million eukaryotic species and is
remarkable with respect to its profound impact on global health, biodiversity, ecol-
ogy, agriculture, manufacturing, and biomedical research. Approximately 625 fungal
species have been reported to infect vertebrates, 200 of which can be human asso-
ciated, either as commensals and members of our microbiome or as pathogens that
cause infectious diseases. These organisms pose a growing threat to human health
with the global increase in the incidence of invasive fungal infections, prevalence of
fungal allergy, and the evolution of fungal pathogens resistant to some or all cur-
rent classes of antifungals. More broadly, there has been an unprecedented and
worldwide emergence of fungal pathogens affecting animal and plant biodiversity.
Approximately 8,000 species of fungi and Oomycetes are associated with plant dis-
ease. Indeed, across agriculture, such fungal diseases of plants include new devastat-
ing epidemics of trees and jeopardize food security worldwide by causing epidemics
in staple and commodity crops that feed billions. Further, ingestion of mycotoxins
contributes to ill health and causes cancer. Coordinated international research ef-
forts, enhanced technology translation, and greater policy outreach by scientists are
needed to more fully understand the biology and drivers that underlie the emer-
gence of fungal diseases and to mitigate against their impacts. Here, we focus on
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poignant examples of emerging fungal threats in each of three areas: human health,
wildlife biodiversity, and food security.
KEYWORDS antifungal resistance, biodiversity, food security, fungal pathogens,
global health, medical mycology, plant-pathogenic fungi, wildlife pathogens
The fungal kingdom includes millions of species (1), ranging from the largestorganism on earth (2) to a myriad of microscopic species, some of which are
pathogenic for plants and animals. For many fungi, the capacity to sense environmental
cues and transition between distinct morphologies has a profound impact on their
ability to reproduce, forage for nutrients, invade tissues, and evade immune responses
(3, 4). In the biosphere, fungi occupy a critical role as degraders of organic matter,
which allows the release and reuse of elements and nutrients from dead organisms (5).
This ability to degrade organic matter, and in particular plant remains, requires complex
enzymatic suites that are also relevant for their role as pathogens because many of
those same proteases, phospholipases, cellulases, hemicellulases, pectinases, ligninase,
and nucleases can play important roles in virulence. Fungi are also remarkable as
factories of secondary metabolites that include such important medical compounds as
antibiotics and immunosuppressants, as well as mycotoxins that can be deleterious to
human, animal, and plant health. Although fungi were historically thought to be related
to plants based on their production of cell walls and the morphology of mushrooms,
molecular analyses in the 1990s showed that they are closer to animals (6). This
phylogenetic relationship hinders the discovery of antifungal drugs to treat human and
animal diseases because it implies that there are fewer metabolic differences suitable
for targets in drug development.
In nature, fungi exist in symbiotic relationships with such diverse species as plants
and algae, to form mycorrhizae and lichens, respectively. Fungi often reside in complex
communities composed of multiple cell types, with biofilms as a predominant life form
(7). Fungi are important members of diverse microbiota and promote ecosystem
homeostasis through interactions with bacteria in lungs, guts, soil, stems, and other
environments (8–10). Although fungi are generally considered auxotrophic, they can
also harvest electromagnetic radiation for growth, which implies some autotrophic
capacity (11–13). Fungi are highly resilient and capable of successfully occupying
extreme environments. For example, the damaged radioactive reactor at Chernobyl
hosts dozens of melanotic fungal species, despite high radiation fluxes (14), and the
Antarctic fungus Cryomyces antarcticus has been shown to survive under space station
simulated Mars conditions (15). Fungi hold the record for growth at elevated temper-
ature among eukaryotic organisms; Aspergillus fumigatus, the major human lung aller-
gen and pathogen, is able to grow at temperatures up to 70°C and remains viable down
to 20°C (16, 17). As illustrated by these examples, fungal species manifest astounding
diversity, resilience, and variability with regard to the environments they occupy and
their associations with other organisms.
Fungi are remarkable in their ability to adapt rapidly in response to selection
pressures. Their capacity for both sexual and asexual reproduction and epigenetic
change and tolerance of changes in genome ploidy underlie their ability to evolve
rapidly in response to selective pressures imposed by heterogeneous and changing
environments. In clinical and agricultural settings, these properties translate to an
ability to readily develop resistance to antifungal agents (18). Similarly, changes in
virulence and thermal tolerance can be elicited in experimental settings over short time
scales. For example, coincubation of amoeba and fungal cells results in rapid increases
in virulence (19–22), and progressive exposure of Metarhizium anisopliae to higher
temperatures results in increased thermal tolerance that allows growth at mammalian
temperatures (23). Hence, there is concern that climate change with global warming
will select for new animal- and human-pathogenic fungi as species with pathogenic
potential adapt to higher temperatures and thus breach mammalian thermal defenses
conferred by endothermy (24). In this context, the simultaneous appearance of phylo-
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genetically distant strains of Candida auris on three continents may be the first example
of a new fungal pathogen emerging due to global warming (25).
In summary, the fungal kingdom presents tremendous opportunities and challenges
to humanity through its remarkable diversity, exceptional metabolic capacity, and rapid
ability to change. In the context of opportunities, the overwhelming majority of fungal
species remain uncharacterized, and these could be the source of new drugs and useful
compounds for industry or have synergistic roles in supporting plant growth in
mineral-limited soils or resisting pathogen invasion (26). In the context of challenges,
the fungal kingdom also includes numerous species with pathogenic potential that
pose threats to varied ecosystems. The fact that the fungal kingdom is understudied
compounds the threats posed by what has been referred to as the “hidden kingdom.”
The realization that much more attention and effort need to be devoted to studying all
aspects of the biology of fungi has led Nature Microbiology to advocate ending this
neglect of fungi (27), the Royal Society to convene a meeting to strategize tackling
emerging fungal threats (28), and the United States Centers for Disease Control and
Prevention (CDC) to organize a fungal disease awareness week. In recognition of the
importance of fungi for the biosphere, the American Academy of Microbiology held a
colloquium in 2017 titled “One Health: Fungal Pathogens of Humans, Animals, and
Plants” (1), which inspired this follow-up article.
EMERGING FUNGAL THREATS TO HUMANS
The impact of fungi on human health has been underappreciated, despite the fact
that these eukaryotic pathogens infect billions of people worldwide, killing in excess of
1.5 million per year (29, 30). Systemic fungal diseases were rare in humans until the
1950s, when antibiotics and the development of intensive care units revolutionized
modern medicine. The 1950s also marked the start of the use of immunosuppressive
agents such as corticosteroids, the development of cancer chemotherapies, and the
inception of catheters that provide access for microbes on the body’s surface to
the body’s interior. These factors enabled fungi to exploit humans in new ways. There
are diverse types of fungal infections that are determined by the fungal species and the
immune status of the person infected (31). Superficial infections are the most common
and include the 1 billion people with skin, hair, and nail infections. Mucosal infections
with Candida (so-called “yeast infection”) are also very common, with over 135 million
women afflicted repetitively, as one example (32). More devastating are chronic,
localized infections below the skin that are more common in tropical regions, as with
mycetoma and chromoblastomycosis, which the World Health Organization (WHO) has
recently classified as Neglected Tropical Diseases. Likewise, chronic fungal lung infec-
tions, notably with Aspergillus spp., are complications of tuberculosis and other chronic
pulmonary diseases, affecting millions globally (33). Fungal allergy is also common,
with millions affected, worsening asthma and cystic fibrosis or leading to chronic nasal
and sinus symptoms (33). Invasive fungal infections are progressive and lethal if not
diagnosed and specifically treated. These infections are initiated by inhalation or
inoculation of spores or by mobilization of commensal fungi that reside within the
body. Although a few species of fungi have the capacity to cause disease even in
healthy people, most invasive fungal infections are caused by fungi with low patho-
genic potential that cause disease only in patients with defects in innate or acquired
immunity, including in the context of premature births, HIV infection, and severe
influenza, as well as due to immunosuppressive treatments for cancer transplantation.
These invasive fungal diseases impose a major public health burden, with mortality
rates of 30% to 90%, depending on the pathogen and patient population.
Approximately 90% of deaths due to fungal infection are caused by species of
Aspergillus, Cryptococcus, Candida, or Pneumocystis, with additional threats posed by
fungi such as Coccidioides and Histoplasma, which can infect even immunocompetent
hosts in regions of endemicity (29, 30). An acute threat is posed by Aspergillus species,
with more than 30 million people at risk of invasive aspergillosis each year because of
corticosteroid or other treatments and over 300,000 patients developing this infection
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annually (34). A. fumigatus is a common culprit, associated with an overall 50%
mortality rate even if diagnosed and treated swiftly. There is a growing appreciation
that Aspergillus and other fungi can be a major cause of life-threatening allergy
associated with severe asthma (35, 36). Cryptococcus species are also now recognized
as one of the most significant fungal threats to human health (37). The WHO places the
annual global burden of cryptococcal meningitis in excess of 223,100 cases annually,
causing more than 181,000 deaths in patients living with HIV and approximately 15%
of all AIDS-associated deaths. Cryptococcosis is caused almost exclusively by two
closely related species that are commonly encountered in the environment: Cryptococ-
cus neoformans and Cryptococcus gattii (38–40). Another AIDS-defining illness has been
Pneumocystis pneumonia, which remains a common infection in resource-limited re-
gions and has expanded to diverse patient populations, including transplant recipients
and individuals afflicted with lung disease, autoimmune disease, or cancers of the
blood or lymph systems (41). In the context of hospital-acquired invasive fungal
infections, species of Candida are the most prevalent causal agent, with Candida
albicans as the most frequent culprit and associated with mortality rates approaching
40% despite state-of-the-art treatment options (42). Current blood culture methods, the
usual means of diagnosing systemic infection, are only 40% sensitive. More sensitive
molecular approaches, such as -glucan detection or PCR testing, are costly and not
widely available, leading to an underestimation of the burden of invasive candidiasis.
The CDC has classified Candida as a serious threat to human health due to the dramatic
rise in drug-resistant infections, especially those caused by non-albicans species (43).
Overall, there is a growing concern regarding the impact of outbreaks of fungal
diseases.
An emerging fungal pathogen that has gained international attention is Candida
auris, which is typically multidrug resistant and frequently implicated in life-threatening
hospital-acquired infections. C. auris poses a new threat to global health due to an
escalating number of cases, a high rate of antifungal resistance, and an ability to survive
in hospital environments, leading to nosocomial outbreaks. Initially reported in cases of
ear infections (44), this species was soon after detected as the cause of contempora-
neous outbreaks in dispersed regions of the world (45, 46). Genomic analyses of these
early cases identified four geographically stratified genetic subdivisions or clades (47).
More recently reported outbreaks are predominantly linked to three of these clades
(48–50), and a fifth potential clade was identified in 2018 from a single isolate from Iran
(51). While in many countries C. auris is still a rare cause of infection, the pathogen is
now responsible for a major proportion of candidemia in other regions (52).
The identification of distinct clades of C. auris in different regions of the world within
the span of a few years is a striking aspect of the emergence of this species. C. auris was
first identified only in 2009, and retrospective inventories of older isolate collections did
not detect the species prior to 1996 (47). Owing to the high frequency of resistance to
azole antifungals, exposure to these chemicals, which are used widely in both medicine
and agriculture, may have played a role in the selection of azole-resistant isolates of C.
auris. The ability of this yeast to colonize skin and to grow at higher temperatures is also
likely to have contributed to the emergence and global dissemination of C. auris.
Factors that could explain how this species only recently became a global human
pathogen include an increase of health care settings that may promote transmission,
human interactions with the environment increasing contact with or amplifying C.
auris, or rising global temperatures selecting for higher-temperature growth tolerance
(25, 53). Currently, unanswered questions include where this species occurred prior to
1996, what was the prepandemic population structure, and whether there is an
environmental reservoir of this fungus that spilled over to infect humans. The closest-
related species of C. auris have been isolated from a variety of marine and terrestrial
environments, in addition to human sources, and wide environmental surveys may help
better delineate the preferred environment and provide clues as to where to search for
C. auris (25, 53). It is pertinent to note that these questions broadly parallel those that
were asked in the context of other fungal outbreaks, such as the global emergence of
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Batrachochytrium dendrobatidis in amphibians (see below), questions that culminated
in the discovery of the Asian origins of amphibian chytridiomycosis 20 years after its
detection (54).
While the ability of C. auris to survive in a hospital environment clearly has played
a role in local outbreaks, the pathogenesis of this fungus is less clear, with contrasting
reports of the virulence of this organism relative to other Candida species (55, 56).
Infected patient populations, while not generally immunocompromised, often have
other major health complications or have undergone recent invasive procedures (47).
Thus, the attributable mortality related to C. auris infection is not yet clear.
Effective health care guidelines to deal with C. auris infections require better
surveillance methods, rapid and accurate diagnostics, decolonization protocols, and
new antifungals to combat multidrug-resistant strains. Identifying patients at high risk,
in addition to those with direct contact to index cases, could be prioritized for skin
colonization screening. Efforts focused on antimicrobial resistance warrant expansion
to include analysis of C. auris. Wider screening would be supported by more rapid and
accessible diagnostic assays, which need to differentiate C. auris from the related
species Candida haemulonii. The high frequency of C. auris resistance to antifungal
drugs, including isolates with reported resistance to all three major classes of antifun-
gals used to treat invasive infections (47, 57), highlights the urgent need for the
development of new antifungal therapies.
Beyond C. auris, there are major concerns for other fungal outbreaks and the rise in
antifungal drug resistance. One pressing threat is posed by the ongoing outbreaks of
Trichophyton infections in Southeast Asia that are resistant to the ergosterol biosyn-
thesis inhibitor terbinafine (58). Strong selection for the emergence of resistance in this
dermatophyte is likely attributable to the widespread use of over-the-counter medica-
tions, incomplete treatment courses, and the use of creams that combine steroids,
antifungals, and antibacterials and are associated with low exposures and incomplete
coverage. Another cause for serious concern has been the alarming increase in azole-
resistant Aspergillus (18, 59–61). Selection for resistance in Aspergillus can occur in
patients on long-term therapy, as well as in regions of intensive agricultural fungicide
use, with Aspergillus being one of the most common globally ubiquitous eukaryotes
and azoles being a dominant fungicide deployed in agriculture. The potential for
azole-resistant Aspergillus to evolve in the field and be transmitted to the clinic has
been highlighted as a major cause for concern. We have little understanding of the
wider impact of the global usage of antifungal chemicals on fungi that reside in the
environment.
CONTROL STRATEGIES
A major limitation to combating the high morbidity and mortality of fungal infec-
tions is the limited application of accurate diagnostic tools. Detection of fungal
infections by microscopy and culture is insensitive and often negative early in infection
when treatment is most effective. There have been many recent commercial develop-
ments in nonculture diagnostics allowing immediate or within-24-h diagnosis for the
most lethal infections, including cryptococcal, Aspergillus and Histoplasma antigen,
Aspergillus antibody, and PCR tests for Candida, Pneumocystis, Aspergillus, Mucormyce-
tes, and dermatophyte infections (62). Real-life experience of these tests, either singly
or collectively, has demonstrated the individual and public health merits of such testing
in many different clinical settings (63–67). Integration of these tests into routine care
pathways in high-risk patient groups requires a major shift in thinking and allocation of
health care resources (68).
Owing to the close evolutionary relationship between fungi and animals, there are
a very limited number of targets for antibiotic therapy that both kill or arrest the fungus
and spare the host. One antifungal target is the cell wall, which is found in fungi and
is absent in animals, and the other is the cell membrane, which contains ergosterol in
fungi and cholesterol in animals. Despite the many challenges in the development of
safe and effective antifungals, there is recent progress in antifungal drug development
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(69). New members of established antifungal classes have been advanced, as evidenced
by the approval of the azole inhibitor of ergosterol synthesis isavuconazole in 2015, and
the ongoing clinical trials of rezafungin—a new member of the cell wall-targeting
echinocandin class that does not require daily dosing. To overcome resistance and offer
opportunities for better overall outcomes, drugs with novel targets are crucial. Much-
needed advances in this space include olorofim, which blocks pyrimidine biosynthesis;
ibrexafungerp, which inhibits -glucan synthesis through a mechanism that is distinct
from that of the echinocandins (70); and fosmanogepix, which inhibits synthesis of
glycosylphosphatidylinositol-anchored cell wall mannoproteins. The potential antifun-
gal drug target space can be further expanded by combining conventional antifungals
with molecules that target key regulators of crucial responses to drug-induced cellular
stress, as with the protein phosphatase calcineurin and molecular chaperone Hsp90 (71,
72). Innovative approaches that move beyond small-molecule antifungals, such as
antifungal vaccines, immunotherapies, and novel antifungal biologics, are also areas of
active investigation (73–76). By harnessing advances in antifungal immunity, chemical
genomic screening platforms, large libraries of diverse synthetic molecules and natural
products, and partnerships between academia and industry, there are exciting oppor-
tunities to develop resistance-evasive strategies to treat life-threatening and chronic
fungal infections (77).
EMERGING FUNGAL THREATS TO WILDLIFE
The animal kingdom is widely infected by fungi, and it is unlikely that an animal
exists that is not colonized or infected by fungi. While insects are extensively infected
by fungi, which are important regulators of insect populations (78), only around 625
fungi have been reported to cause infection in vertebrates (79). As with humans,
resistance of vertebrate wildlife to fungi is a function of both innate and acquired
immunity, bolstered by high body temperatures in endothermic mammals and birds.
These factors ensure a high degree of resilience of vertebrates to the fungi that they are
exposed to, and as a consequence, fungal disease in animals is often associated with
compromised immunity. Nonetheless, trends have shown that emerging fungal dis-
eases in animals are occurring worldwide (80). The factors that underlie this expansion
of disease are multifactorial and are underpinned by the complex interactions among
biotic and abiotic drivers described in Fig. 1. Host life-history plays an important role in
determining susceptibility, and emerging fungal pathogens of wildlife such as frogs,
salamanders, bats, and snakes circumvent resistance to infection mediated by high
body temperature through infection of nonthermoregulating amphibians and reptiles
or hibernating mammalian hosts.
Two fungal genera have acquired recent notoriety through causing very aggressive
emerging infections associated with die-offs, population declines, and, in some cases,
vertebrate species extinctions. These are the aquatic chytrid fungi Batrachochytrium
dendrobatidis and Batrachochytrium salamandrivorans causing chytridiomycosis in sus-
ceptible species of amphibians, and the ascomycete fungus Pseudogymnoascus destruc-
tans causing white-nose syndrome (WNS) in hibernating bats of North America. In both
cases, the unifying factor explaining the original emergence of these pathogens is the
international dispersal of infectious inocula, which has ignited outbreaks of disease in
naive host populations, followed by invasion across landscapes and host communities.
Within a year of the 1998 report of chytridiomycosis in pristine environments in
Central America and Australia (81), the fungal agent was named, Batrachochytrium
dendrobatidis sp. nov. (82), and in the ensuing 2 decades this fungus has been found
infecting species across all continents except for the amphibian-free Antarctica (83).
While Batrachochytrium was initially classified as a monotypic genus, the extirpation of
fire salamanders in the Netherlands by chytridiomycosis led to the discovery of a
pathogen from the same genus in 2013—Batrachochytrium salamandrivorans sp.
nov.—proving that this genus harbored further undescribed pathogen diversity posing
a further threat to amphibian biodiversity (84). Together, this class of pathogens is
known as the batrachochytrids (85). To assess the impacts of batrachochytrids on
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global amphibian populations, Scheele et al. (86) synthesized data from multiple
sources of information spanning peer-reviewed studies, the International Union for
Conservation of Nature (IUCN) Red List of Threatened Species, and consultations with
the scientists investigating the declines as they occurred (87) and retrospectively (88,
89). This global meta-analysis revealed that chytridiomycosis has contributed to the
decline of an estimated 6.5% of extant amphibian species, including the extinction of
90 different species and representing the greatest documented loss of biodiversity
attributable to any invading microorganism.
While the origins of B. dendrobatidis were long shrouded in mystery, recent phy-
logenomic analysis developed multiple lines of evidence identifying the Korean pen-
insula as the most likely center of origin for the panzootic (54). At least three lineages
of B. dendrobatidis appear to have escaped out of Asia, with molecular dating showing
that the expansion of the B. dendrobatidis Global Panzootic Lineage (BdGPL) had its
origins during the first half of the 20th century. The most recent out-of-Asia emergence
explains the outbreak of B. salamandrivorans in the Netherlands following an introduc-
FIG 1 The drivers of emerging fungal threats to plants and animals. Four key factors favor the emergence of fungi that infect plants and animals. (i) Evolutionary
potential (blue boxes). High pathogen abundance and virulence enhance evolutionary potential. A rapid and repeating life-cycle generates a large pathogen
population density. High genetic strain diversity hastens emergence of novel fungal genotypes and lineages, with diversity generated by enhanced
reproductive capacity (sexual, parasexual, or clonal), whole-genome or hyphal fusions (144), or genome plasticity endowed by aneuploidy/copy number
variation (145), horizontal gene transfer (146), or two-speed genomes (147). (ii) Artificial selection and host susceptibility (gray boxes). A homogeneous host,
such as a large population of animals or a crop monoculture, fuels pathogen variant emergence. Fungicide-resistant genotypes emerge due to protracted and
repeated treatments/sprays and via the dual use of antifungals on crops and in the clinic (18). (iii) Dispersal/epidemiology (red boxes). Pathogens and infected
hosts are disseminated globally via movement of infected biota (85), contamination of traded goods, or long-distance spore dispersal by, for example, airplanes
or vectoring by hurricane winds (119, 148). Fungi can persist long-term as resting spores or via saprophytic growth. They can hop hosts or persist as generalist
pathogens by causing infections on multiple hosts (18). Transmission can be enhanced by extended phenotypes (149), while coinfections, polyparasitism, and
transkingdom interactions can mitigate or fuel the emergence of novel strains) (85). (iv) Environmental permissiveness (green boxes). Anthropogenic and
meteorological amplifiers of fungal pathogen emergence include population growth, changing population demography fueled by urbanization or conflict,
aging, immunosuppression, and nosocomial hospital-acquired infections. A warming world, with increased incidences of dramatic/extreme weather events and
a change in the amounts of, for example, CO2 and N2O (150), has the potential to further fuel the emergence of fungal pathogens.
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tion event from its endemic range in Vietnam (90). Other intercontinental and trans-
national introductions are occurring today for both batrachochytrids because of the
global amphibian trade (54) and translocated species (91).
The outbreak of white-nose syndrome (WNS) in North American bats appears to be
similarly explained by the recent introduction of this pathogen from a European center
of endemism (92). The pathogen concerned, P. destructans, has killed millions of North
American hibernating bats since emergence in New York State in approximately 2006
(93), and as of 2020, the pathogen had spread to 38 U.S. states and seven Canadian
provinces (U.S. Fish and Wildlife Service; https://www.whitenosesyndrome.org/where
-is-wns). The causative fungus of WNS is an obligate psychrophile that grows optimally
between 12.5 and 15.8°C (54.5 and 60.4°F, respectively) with an upper growth limit of
about 20°C (68°F) (94). As metabolically active bats have a body temperature of
approximately 37°C, the fungal pathogen evades this limitation by infecting susceptible
bat hosts during hibernation, when their core body temperatures are reduced to
approximately 7°C. While mortality of hibernating bats from WNS can exceed 90% at
some underground hibernation sites, for infected bats that survive until spring, emer-
gence from hibernation can clear the fungal infection after they return to a euthermic
body temperature above that conducive to growth of P. destructans (95).
A striking similarity between the batrachochytrids and P. destructans is that they are
all cutaneous pathogens. While dermatophytic skin infections are typically considered
to be superficial, the skin of amphibians and wing skin of bats are known to mediate
complex physiological functions beyond service as a mechanical barrier, including gas
exchange, electrolyte balance, and water homeostasis (96). Consequently, damage to
the skin of infected amphibian and bat hosts has far-reaching physiological conse-
quences. In amphibians, fungal skin infection has been experimentally demonstrated to
cause electrolyte imbalance leading to death by cardiac arrest (97). In hibernating bats,
fungal skin infection causes chronic respiratory acidosis and hyperkalemia, disrupting
hibernation and inducing increased energy use in animals reliant on a strategy of
energy conservation to survive winter food shortages until spring emergence (98).
Thus, fungal skin infections of wildlife are not only causing catastrophic population
declines but doing so through mechanisms not previously known in human or veter-
inary medicine, presenting novel challenges for mitigating these impacts.
CONTROL STRATEGIES
While a sophisticated infrastructure exists to rapidly tackle outbreaks of human
and agricultural pathogens, the knowledge and toolkits to combat emerging
diseases in wild populations are nearly nonexistent. For instance, from the detec-
tion of batrachochytrid-driven amphibian declines through to the development of
management plans and description of these disease sources took almost 3 decades
(99). For WNS in bats, this timeline has been compressed, but positive outcomes
continue to be hindered by limited available management options. Nonetheless,
lessons have been learned and toolboxes of interventions for emerging wildlife dis-
eases have been developed that broadly mirror the frameworks used for invasive
species (100).
Management options are classified into four categories based on the stages of the
pathogen invasion process—prearrival, invasion front, epizootic, and established—and
are implemented as appropriate. Considering the batrachochytrids, control prearrival is
focused on preventing introduction of the pathogens. Biosecurity is a first line of
defense, and management actions are through strengthening import controls on
disease vectors and establishment of an infection-free trade (101). For example, and
motivated by the discovery of B. salamandrivorans, the European Union has imple-
mented health protection measures for the trade of salamanders (102); similar mea-
sures have been adopted by the United States (103) and Canada (104). These preemer-
gence prearrival biosecurity-oriented strategies remain the best option for avoiding
disease emergence and need to be more widely adopted in the context of broadly
controlling fungal pathogens of wildlife, such as bat WNS.
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Following emergence along the fungal invasion front, management actions are
focused on pathogen eradication, minimizing the risk of population extinction, and
reducing further geographic spread. The range of management actions that are suit-
able for a particular pathogen-host combination can be explored through decision
processes by, for instance, the use of integral projection models. This approach has
been used to explore the potential control of B. salamandrivorans’s spread in Europe
through the following management actions: (i) no action, (ii) improving host body
condition, (iii) host probiotic treatments, (iv) host antifungals, and (v) host pre- and
postdetection culling. Due to the high virulence of B. salamandrivorans in fire salaman-
ders, the decision analysis concluded that these actions were unlikely to be effective
under anything except perfect situations (105). That said, successful eradication of B.
dendrobatidis from geographically isolated sites in Mallorca, Spain, using the antifungal
itraconazole alongside an environmental disinfectant shows that sustained control can
lead to the local eradication of a batrachochytrid (106). In the case of bats and WNS,
strategies to control P. destructans, such as probiotic treatments (107), UV-mediated
killing of the fungal pathogen (108), or disinfection of environmental reservoirs, have
also been tested or proposed. To date, efforts to mitigate WNS have been impeded by
logistical challenges of working with hibernating animals sensitive to disturbance in
complex underground environments, and beneficial outcomes have not yet been
clearly demonstrated.
Once established in the epizootic and established phases, management actions
necessarily shift from limiting spread to reducing impacts on host populations. Options
here include vaccination (109, 110) or bioaugmentation with probiotics (107, 111),
manipulating habitats to favor the host over the pathogen, facilitated evolution or
host-translocation of disease-resistant individuals, and ex situ conservation of highly
threatened species. The safeguarding of threatened species through establishing ex situ
captive breeding programs currently remains the only active conservation method to
avoid species loss after invasion, and Amphibian Arks maintains the possibility for
selective breeding or genetic modification of amphibians for resistance (112). Advances
in gene editing represent a novel and potentially transformative tool for management
of disease in free-ranging wildlife, providing possible avenues to augment host im-
mune responses to, or attenuate virulence of, fungal pathogens (101, 113). However, as
response-based control of disease in free-ranging wildlife presents challenges on
numerous fronts, as with additional emerging threats such as that posed by snake
fungal disease (114), investment in prevention-based strategies that support resilient
wildlife populations with the capacity to adapt to health threats in the absence of
routine human intervention would constitute a key component of prearrival disease
control.
EMERGING THREATS TO PLANTS
Plant-infecting fungi and oomycetes challenge the integrity of natural ecosystems
and jeopardize global food security (80, 115). Indeed, we face a future blighted by
known adversaries, new variants of old foes, and new diseases. Modern agricultural
intensification practices, in particular, have heightened the challenge, as the planting of
vast swathes of genetically uniform crops, guarded by one or two inbred resistance (R)
genes, and use of single-target antifungals have accelerated the emergence of new
virulent and fungicide-resistant strains. Climate change compounds the saga as we see
altered disease demographics—pathogens are moving poleward in a warming world
(116). It now becomes critical that we better understand how plant pathogens move in
time and space and the mechanisms by which they evolve. Population data, collected
over various spatial scales, are pivotal to the success of this endeavor.
Wild species. Fungi and oomycetes threaten the longevity and viability of natural
ecosystems through infection and then decimation of wild hosts. For example, infection
destroys standing trees, affecting carbon sequestration and causing habitat loss for the
resident or local natural flora and fauna. While many pathogens cause persistent
disease problems, such as root rot of trees, others have already changed the landscape,
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such as Dutch elm disease (Ophiostoma novo-ulmi) and chestnut blight (Cryphonectria
parasitica) (80), and thus are considered to be largely “historical” diseases. More
recently, however, there have been new disease incursions, such as myrtle rust (Aus-
tropuccinia psidii) and ash dieback (Hymenoscyphus fraxineus) (117). Both diseases are
spreading around the world, challenging not only their hosts per se but with myrtle rust
having the potential to spread to other Myrtaceae species, for example, eucalyptus and
tea trees (118), and with dieback threatening not only the ash genus but also other
family members in the Oleaceae (117).
Crops. Global food insecurity, caused by infection and subsequent decimation of
our crops, comes in two guises, as it derives from (i) pre- or postharvest loss of calorie
crops—that is, loss of staples that provide calories for local and national consump-
tion—and (ii) loss of commodity or cash crops, which are traded globally and where
economies of whole countries depend upon export revenues to access food grown
elsewhere in the world (119).
(i) Calorie crops. The top five global calorie crops are wheat, rice, maize, oil palm,
and soybean, as derived from measuring crop yield with the metric of calories per capita
per day (FAOSTAT 2016; http://faostat.fao.org/default.aspx). Of these, wheat and soy-
bean harvests are currently under threat from newly emerged fungal and oomycete
pathogens. They are, respectively, the wheat blast fungus, Magnaporthe oryzae; the
soybean rust fungus, Phakopsora pachyrhizi (120, 121);and the soybean oomycete
pathogen Phytophthora sojae (121). We focus further on the wheat blast fungus
because it serves as a cautionary example regarding global trade without robust plant
health legislation and highlights the urgent need for immediate data dissemination via
“open science,” by the international team of scientists involved (122).
The wheat blast fungus Magnaporthe oryzae (also known as Pyricularia graminis-
tritici) was first described in 1985 in Brazil. It subsequently spread across central and
southern Brazil (1988) and has since been reported in Bolivia, Paraguay, and Argentina
(1996 to 2007) (123). In 2016, the fungus arrived in southwestern Bangladesh (124) and
has since devastated the wheat harvest in eight districts, with total loss of crop and
accounting for the loss of circa 3.5% of the total Bangladeshi wheat harvest (abstracted
from 2016 USDA Foreign Agricultural drive BG6005; https://www.fas.usda.gov/data/
Bangladesh-grain-and-feed-annual). The sudden arrival of wheat blast posed a series of
questions. Where had it come from? Would the epidemic spread both within the
country and to neighboring countries? Would disease impact the daily Bangladeshi diet
by loss of calories? Could disease-resistant cultivars be deployed for planting? A
consortium of United Kingdom, Bangladeshi, Swiss, and French scientists joined forces
in a field pathogenomics and population genetics study to gather, sequence, and
analyze the pathogen on diseased field-harvested wheat leaves (122). Their combined
phylogenomics expertise led to the conclusion that the fungus had been introduced
into Bangladesh from South America (124). Their findings were validated when “rotten
wheat” was reported to have been imported from Brazil into Bangladesh in 2015 (124),
attesting to poor phytosanitary practices at both point of export and point of import.
Such international engagement, with sequence data released quickly onto an open-
science web-based platform (http://www.Wheatblast.net), was unprecedented in the
field of plant-pathogen studies.
This disease incursion and its outcome highlight four key points: (i) the need for avid
disease surveillance, that is, scrutiny of imported goods and in the field, particularly
under environmental conditions conducive to disease spread; (ii) the need for imme-
diate data-sharing with other scientists, politicians, and the public alike for use in policy
making; (iii) the need to breed wheat resistant to wheat blast infection, whether by
traditional breeding (e.g., by global breeding programs as coordinated by CIMMYT, the
International Maize and Wheat Improvement Center), by identification of R genes, or via
CRISPR-edited wheat lines (122); and (iv) the need to understand the changing profile
of local diets, such as the increasing amount of wheat eaten in Bangladesh (now 18%
of the daily diet), both homegrown and from rising wheat imports.
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(ii) Commodity crops. The top commodity crops are far harder to define than
calorie crops (125). However, here we consider bananas as a major cash crop, on which
the livelihoods of tens of thousands of those dwelling in Africa, Central and South
America, and Asia depend, and focus on the challenge of Panama disease of bananas
caused by Fusarium oxysporum f. sp. cubense Tropical Race 4 (TR4).
Bananas (Musa spp.) are the most consumed, the cheapest, and the most traded
global fruit (126). They are, in fact, the fifth most traded agricultural product. While ca.
100 billion bananas are thought to be consumed each year (Bananalink, https://www
.bananalink.org.uk/), precise figures on global banana production are elusive, as many
are grown by smallholder farmers, particularly in Africa, Asia, and Latin America and are
traded and consumed locally. Commercial bananas are triploids that do not produce
mature seeds and are propagated vegetatively (127). There are hundreds of different
varieties worldwide (127), but the most widely traded banana, from the Cavendish
subgroup, accounts for approximately 47% of global production, with ca. 100 million
tons produced globally each year (FAOSTAT, www.fao.org). As such, this is a precious
cash or commodity crop, particularly in countries such as Ecuador, Philippines, and
Costa Rica. To illustrate this point, in terms of food security, Costa Rica exports 13%
of the world’s trade in bananas, and the revenue generated covers 40% of Costa
Rica’s food imports (abstracted from http://www.fao.org/economic/est/est-commodities/
bananas).
Cavendish bananas are widely planted and dominate the U.S. and European Union
import markets, being higher yielders, more resilient to extremes of weather, and more
robust in transit than other cultivars. However, their hugely restricted genetic basis is
a matter of grave concern for global banana production. Indeed, the longevity of the
Cavendish banana is jeopardized by the spread of an aggressive fungus, F. oxysporum
f. sp. cubense (Fusarium odoratissimum) TR4. Infection of Cavendish and many other
banana varieties (126) causes wilting, leaf chlorosis, vascular discoloration, and loss of
crop. TR4 was first described in Malaysia, Indonesia, and China (1990s) and then
Australia (1997), Jordan and Mozambique (2013), Europe (2018), and Turkey (2019)
(128), and its first incursion into Latin America, notably Colombia, was recorded in 2019
(129). This fungus persists in the soil or on decaying host plant debris, with chlamy-
dospores allegedly remaining viable for up to 30 years (126). TR4 invades susceptible
roots and causes severe vascular wilt disease. Descriptions of root infection and
subsequent colonization of the rhizome (130, 131), and progression of the fungus
through to the pseudostem (132) and aerial tissues (133), have generated greater
understanding of its infection cycle. There remain, however, many unknown details
regarding both the biology of whole-plant infection and the pathogen characteristics
that drive its spread.
Current efforts involve sequencing of F. oxysporum f. sp. cubense populations,
including TR4 and other races from different geographical locations. A goal of popu-
lation genomic analyses will be to decipher the origin and spatiotemporal migration
routes in time and space of the pathogen and to identify the race-specific mutations or
genomic regions that define TR4. Genome sequencing of other F. oxysporum forma
specialis fungi has revealed that this group of fungi comprise highly dynamic genomes
(134, 135). For example, the genome of the tomato-infecting lineage F. oxysporum f. sp.
lycopersici includes highly variable lineage-specific chromosomes encoding virulence
determinants that are essential for virulence. F. oxysporum propagates mainly by clonal
reproduction; however, lineage-specific chromosomes can be exchanged horizontally
between strains (135). Thereby, new virulence determinants can be acquired or ex-
changed between strains by vegetative fusion. It is possible that the virulence speci-
ficities of TR4 and other F. oxysporum f. sp. cubense races likewise are encoded by
lineage-specific chromosomes.
CONTROL
There are currently no commercial banana cultivars resistant to TR4. Interestingly,
wild banana species surveyed in natural forests of Indonesia in proximity to banana
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plantations infected by TR4 showed no symptoms of Fusarium wilt (136). This obser-
vation points to wild banana species as a potential source of Fusarium wilt resistance
genes. Improving disease resistance in commercial banana cultivars will be an impor-
tant way forward as there are no effective fungicides described to date, and thus,
disease control can currently be affected only by quarantine and hygiene.
Current global disease control for crops largely relies on chemical application that
threatens the health of humans and animals, negatively impacts ecosystems, and
generates drug-resistant plant-pathogenic strains. Innovative and ecofriendly fungi-
cides and antimicrobial agents are in urgent need to avoid uncontrollable outbreaks of
pathogen and parasite infections in both plants and animals, including humans. There
may also be opportunities for development of biological control strategies with envi-
ronmental microbes that produce pathogen-specific antimicrobial agents.
One alternative rapid approach is to utilize cross-kingdom RNA interference (RNAi)
to express double-stranded RNAs (dsRNAs) or small RNAs (sRNAs) that target pathogen
or insect virulence-related genes in plants to combat plant diseases (137–139). This
approach can also control multiple pathogens simultaneously by designing dsRNA and
sRNA constructs that target genes from different pathogens (140). Furthermore, the
recent discovery of fungal RNA uptake (140) makes it possible to develop spray-induced
gene silencing (SIGS) to control fungal pathogens through topical application of
pathogen gene-targeting dsRNAs or sRNAs (140–142). Spray application of long dsRNAs
or sRNA duplexes that target fungal virulence-related genes can effectively suppress
infection of Botrytis cinerea and Sclerotinia sclerotiorum (140, 142) on fruits, vegetables,
and flowers and control Fusarium graminearum infection on the monocot barley (141).
Such RNA-based, “new-generation” fungicides may serve as an effective alternative for
disease control by targeting any pathogen that can take up RNAs and has effective
RNAi machinery and for which important virulence genes are known.
Finally, changing the architecture of agricultural ecosystems by increasing diversity
may carry the potential to reduce disease pressure on crops (143). Species mixtures, as
opposed to monocultures, reduce the spread of fungal pathogens within fields and
may thereby also slow down the evolution of new virulence traits. Further, mixed-
cropping systems have the potential to increase soil microbial diversity, including
mutualistic symbionts that add to improved plant health. Challenges of mixed-
cropping systems will be to alleviate yield damage and to develop technical solutions
to manage crop diversity.
THE WAY FORWARD
In summary, it is clear that interdisciplinary research networks are needed to tackle
four grand challenges presented by fungi: (i) understand the forces driving the emer-
gence, evolution, and spread of fungi affecting plants, animals, humans, and society; (ii)
identify mechanisms of fungal adaptation and interactions with hosts and other
microbes; (iii) understand the evolution of resistance to fungicides and antifungals
across the fungal kingdom; and (iv) implement current successful diagnostic ap-
proaches and develop novel strategies to thwart fungal disease. With human activity,
modern medicine, and environmental and climate change all intensifying the impact of
fungi (29, 80), it is now crucial to mobilize such networks to solve the most pressing
threats to global health, agriculture, and biodiversity.
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